<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ETODOLAC- etodolac tablet, film coated </strong><br>Apotex Corp.<br></p></div>
<h1>
<span class="Bold">ETODOLAC TABLETS, USP <br>400 mg and 500 mg</span><br><br><span class="Bold">Rx only</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
</div>
</div>
<div class="Warning">
<a name="_833c1232-9945-5672-8dce-49ddbdd061f2"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Bold">Cardiovascular Thrombotic Events</span></span></p>
<ul>
<li>Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see <span class="Bold"><a href="#s25">WARNINGS</a></span> and<span class="Bold"><a href="#s36"> PRECAUTIONS</a>)</span>.  </li>
<li>Etodolac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s25">WARNINGS</a></span>).</li>
</ul>
<p><span class="Bold">Gastrointestinal Risk</span></p>
<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at a greater risk for serious gastrointestinal (GI) events (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).</li></ul>
<p><span class="Bold"></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s5"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION </h1>
<p class="First">Etodolac is a member of the pyranocarboxylic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Etodolac is a racemic mixture of [+]S and [-]R-enantiomers. Etodolac is a white crystalline compound, insoluble in water but soluble in alcohols, chloroform, dimethyl sulfoxide, and aqueous polyethylene glycol. </p>
<p>The chemical name is (±) 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid. The molecular weight of the base is 287.37. It has a pKa of 4.65 and an n-octanol:water partition coefficient of 11.4 at pH 7.4. The molecular formula for etodolac is C<span class="Sub">17</span>H<span class="Sub">21</span>NO<span class="Sub">3</span>, and it has the following structural formula: </p>
<div class="Figure">
<a name="f1"></a><img alt="etodolac-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4d682f98-1e8a-4c2b-6df3-169d2ed10dc1&amp;name=etodolac-01.jpg">
</div>
<p><span class="Italics"></span></p>
<p>Each etodolac tablet, USP is for oral administration, contains 400 mg or 500 mg of etodolac. In addition, each tablet contains the following inactive ingredients: crospovidone, hydroxypropyl cellulose, hypromellose, magnesium stearate, methylcellulose, polyethylene glycol and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s6"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43681-6">
<a name="s7"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics </h2>
<p class="First">Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of etodolac, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition. </p>
<p>Etodolac is a racemic mixture of [-]R- and [+]S-etodolac. As with other NSAIDs, it has been demonstrated in animals that the [+]S-form is biologically active. Both enantiomers are stable and there is no [-]R to [+]S conversion <span class="Italics">in vivo</span>. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s8"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.2.1"></a><p></p>
<h3><span class="Bold Italics">Absorption </span></h3>
<p class="First">The systemic bioavailability of etodolac is 100% as compared to solution and at least 80% as determined from <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance studies. Etodolac is well absorbed and had a relative bioavailability of 100% when 200 mg capsules were compared with a solution of etodolac. Based on <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance studies, the systemic availability of etodolac from either the tablet or capsule formulation is at least 80%. Etodolac does not undergo significant first-pass metabolism following oral administration. Mean (± 1 SD) peak plasma concentrations (C<span class="Sub">max</span>) range from approximately 14 ± 4 to 37 ± 9 μg/mL after 200 to 600 mg single doses and are reached in 80 ± 30 minutes (see <a href="#t1">Table 1</a> for summary of pharmacokinetic parameters). The dose-proportionality based on the area under the plasma concentration-time curve (AUC) is linear following doses up to 600 mg every 12 hours. Peak concentrations are dose proportional for both total and free etodolac following doses up to 400 mg every 12 hours, but following a 600 mg dose, the peak is about 20% higher than predicted on the basis of lower doses. The extent of absorption of etodolac is not affected when etodolac is administered after a meal. Food intake, however, reduces the peak concentration reached by approximately one-half and increases the time to peak concentration by 1.4 to 3.8 hours. </p>
<a name="t1"></a><table rules="all" width="100%">
<caption><span>Table 1. Mean (CV%)<span class="Sup">†</span> Pharmacokinetic Parameters of Etodolac in Normal Healthy Adults and Various Special Populations </span></caption>
<col align="left" width="14.440%">
<col align="left" width="11.407%">
<col align="left" width="9.508%">
<col align="left" width="9.508%">
<col align="left" width="9.508%">
<col align="left" width="9.508%">
<col align="left" width="9.508%">
<col align="left" width="13.307%">
<col align="left" width="13.307%">
<tfoot>
<tr class="First"><td align="left" colspan="9" valign="top"><p class="First Footnote"><span class="Sup">†</span>% Coefficient of variation </p></td></tr>
<tr><td align="left" colspan="9" valign="top"><p class="First Footnote"><span class="Sup">*</span>Age Range (years) </p></td></tr>
<tr class="Last"><td align="left" colspan="9" valign="top"><p class="First Footnote">N/A = not available </p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" rowspan="2" valign="top">
<br>PK<br>Parameters<br>
</td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Normal<br>Healthy<br>Adults<br>(18-65)*<br>(n=179) </td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Healthy<br>Males<br>(18-65)<br><br>(n=176) </td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Healthy<br>Females<br>(27-65)<br><br>(n=3) </td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Elderly<br>(&gt;65)<br>(70-84) </td>
<td align="center" colspan="2" valign="top">Hemodialysis<br>(24-65)<br>(n=9) </td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Renal<br>Impairment<br>(46-73)<br><br>(n=10) </td>
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Hepatic<br>Impairment<br>(34-60)<br><br>(n=9) </td>
</tr>
<tr>
<td align="center" valign="top">Dialysis<br>On </td>
<td align="center" valign="top">Dialysis<br>Off </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">T<span class="Sub">max,</span> h </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.4<br>(61%)<span class="Sup">†</span>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.4<br>(60%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.7<br>(60%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.2<br>(43%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.7<br>(88%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">0.9<br>(67%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">2.1<br>(46%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">1.1<br>(15%) </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Oral Clearance,<br>mL/h/kg<br>(CL/F) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">49.1<br>(33%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">49.4<br>(33%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">35.7<br>(28%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">45.7<br>(27%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">58.3<br>(19%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">42.0<br>(43%) </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left" valign="top">Apparent Volume of Distribution, mL/kg (Vd/F) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">393<br>(29%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">394<br>(29%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">300<br>(8%)<br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="top">414<br>(38%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left" valign="top">Terminal Half-Life, h </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">6.4<br>(22%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">6.4<br>(22%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">7.9<br>(35%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">6.5<br>(24%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">5.1<br>(22%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">7.5<br>(34%) </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">N/A </td>
<td class="Lrule Rrule Toprule" align="center" valign="top">5.7<br>(24%) </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.2.2"></a><p></p>
<h3><span class="Bold">Distribution </span></h3>
<p class="First">The mean apparent volume of distribution (Vd/F) of etodolac
is approximately 390 mL/kg. Etodolac is more than 99% bound to plasma proteins,
primarily to albumin. The free fraction is less than 1% and is independent
of etodolac total concentration over the dose range studied. It is not known
whether etodolac is excreted in human milk; however, based on its physical-chemical
properties, excretion into breast milk is expected. Data from <span class="Italics">in
vitro</span> studies, using peak serum concentrations at reported therapeutic
doses in humans, show that the etodolac free fraction is not significantly
altered by acetaminophen, ibuprofen, indomethacin, naproxen, piroxicam, chlorpropamide,
glipizide, glyburide, phenytoin, and probenecid. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.2.3"></a><p></p>
<h3><span class="Bold">Metabolism </span></h3>
<p class="First">Etodolac is extensively metabolized in the liver. The role,
if any, of a specific cytochrome P450 system in the metabolism of etodolac
is unknown. Several etodolac metabolites have been identified in human plasma
and urine. Other metabolites remain to be identified. The metabolites include
6-, 7-, and 8-hydroxylated-etodolac and etodolac glucuronide. After a single
dose of 14C-etodolac, hydroxylated metabolites accounted for less than 10%
of total drug in serum. On chronic dosing, hydroxylated-etodolac metabolite
does not accumulate in the plasma of patients with normal renal function.
The extent of accumulation of hydroxylated-etodolac metabolites in patients
with renal dysfunction has not been studied. The hydroxylated-etodolac metabolites
undergo further glucuronidation followed by renal excretion and partial elimination
in the feces. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.2.4"></a><p></p>
<h3><span class="Bold">Excretion </span></h3>
<p class="First">The mean oral clearance of etodolac following oral dosing is 49 (±16) mL/h/kg. Approximately 1% of an etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite: </p>
<table rules="rows" width="60%">
<col align="center" width="66.000%">
<col align="center" width="34.000%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">-  etodolac, unchanged </td>
<td align="right" valign="top">1% </td>
</tr>
<tr>
<td align="left" valign="top">-  etodolac glucuronide </td>
<td align="right" valign="top">13% </td>
</tr>
<tr>
<td align="left" valign="top">-  hydroxylated metabolites (6-, 7-, and 8-OH) </td>
<td align="right" valign="top">5% </td>
</tr>
<tr>
<td align="left" valign="top">-  hydroxylated metabolite glucuronides </td>
<td align="right" valign="top">20% </td>
</tr>
<tr class="Last">
<td align="left" valign="top">-  unidentified metabolites </td>
<td align="right" valign="top">33% </td>
</tr>
</tbody>
</table>
<p>Although renal elimination is a significant pathway of excretion for etodolac metabolites, no dosing adjustment in patients with mild to moderate renal dysfunction is generally necessary. The terminal half-life (t<span class="Sub">½</span><span class="Sub"></span>) of etodolac is 6.4 hours (22% CV). In patients with severe renal dysfunction or undergoing hemodialysis, dosing adjustment is not generally necessary. </p>
<p>Fecal excretion accounted for 16% of the dose. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s13"></a><a name="section-2.3"></a><p></p>
<h2>Special Populations </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.3.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Geriatric</span><br>In etodolac clinical studies, no overall differences in safety or effectiveness were observed between these patients and younger patients. In pharmacokinetic studies, age was shown not to have any effect on etodolac half-life or protein binding, and there was no change in expected drug accumulation. Therefore, no dosage adjustment is generally necessary in the elderly on the basis of pharmacokinetics (see <span class="Bold"><a href="#s62">PRECAUTIONS, Geriatric Use</a></span>). </p>
<p>Etodolac is eliminated primarily by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#s31">WARNINGS, </a></span><span class="Bold Italics"><a href="#s31">Renal Effects</a></span><span class="Bold"></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.3.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Pediatric </span><br>Safety and effectiveness in pediatric patients below the age of 18 years have not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-2.3.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Race </span><br>Pharmacokinetic differences due to race have not been identified. Clinical studies included patients of many races, all of whom responded in a similar fashion. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-2.3.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> </span><br>Etodolac is predominantly metabolized by the liver. In patients with compensated <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, the disposition of total and free etodolac is not altered. Patients with acute and chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic diseases</span> do not generally require reduced doses of etodolac compared to patients with normal hepatic function. However, etodolac clearance is dependent on liver function and could be reduced in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>. Etodolac plasma protein binding did not change in patients with compensated <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> given etodolac. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-2.3.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span> </span><br>Etodolac pharmacokinetics have been investigated in subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. Etodolac renal clearance was unchanged in the presence of mild-to-moderate <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (creatinine clearance 37 to 88 mL/min). Furthermore, there were no significant differences in the disposition of total and free etodolac in these patients. However, etodolac should be used with caution in such patients because, as with other NSAIDs, it may further decrease renal function in some patients. In patients undergoing hemodialysis, there was a 50% greater apparent clearance of total etodolac, due to a 50% greater unbound fraction. Free etodolac clearance was not altered, indicating the importance of protein binding in etodolac's disposition. Etodolac is not significantly removed from the blood in patients undergoing hemodialysis. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s19"></a><a name="section-3"></a><p></p>
<h1>CLINICAL TRIALS </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> </span></h2>
<p class="First">Controlled clinical trials in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> were single-dose, randomized, double-blind, parallel studies in three <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> models, including dental extractions. The analgesic effective dose for etodolac established in these <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> models was 200 to 400 mg. The onset of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> occurred approximately 30 minutes after oral administration. Etodolac 200 mg provided efficacy comparable to that obtained with aspirin (650 mg). Etodolac 400 mg provided efficacy comparable to that obtained with acetaminophen with codeine (600 mg + 60 mg). The peak <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> was between 1 to 2 hours. Duration of relief averaged 4 to 5 hours for 200 mg of etodolac and 5 to 6 hours for 400 mg of etodolac as measured by when approximately half of the patients required remedication. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-3.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> </span></h2>
<p class="First">The use of etodolac in managing the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the hip or knee was assessed in double-blind, randomized, controlled clinical trials in 341 patients. In patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee, etodolac, in doses of 600 to 1000 mg/day, was better than placebo in two studies. The clinical trials in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> used b.i.d. dosage regimens. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-3.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> </span></h2>
<p class="First">In a 3-month study with 426 patients, etodolac 300 mg b.i.d. was effective in management of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> and comparable in efficacy to piroxicam 20 mg/day. In a long-term study with 1,446 patients in which 60% of patients completed 6 months of therapy and 20% completed 3 years of therapy, etodolac in a dose of 500 mg b.i.d. provided efficacy comparable to that obtained with ibuprofen 600 mg q.i.d. In clinical trials of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> patients, etodolac has been used in combination with gold, d-penicillamine, chloroquine, corticosteroids, and methotrexate. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s23"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First">Carefully consider the potential benefits and risks of etodolac and other treatment options before deciding to use etodolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). </p>
<p>Etodolac tablets, USP are indicated:</p>
<ul class="Disc">
<li>For acute and long-term use in the management of signs and symptoms of the following:<ol class="Arabic">
<li><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid arthritis</span> </li>
</ol>
</li>
<li>For the management of <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> </li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s24"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">Etodolac is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to etodolac. </p>
<p>Etodolac should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see <span class="Bold"><a href="#s33">WARNINGS, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> </a></span>and <span class="Bold"><a href="#s40">PRECAUTIONS, </a></span><span class="Bold Italics"><a href="#s40">Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span><span class="Bold"></span>). </p>
<ul><li>In the setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).</li></ul>
<p></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s25"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<p class="First"><span class="Bold">Cardiovascular Effects</span></p>
<p><span class="Bold Italics">Cardiovascular Thrombotic Events</span><br>Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.</p>
<p>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as etodolac, increases the risk of serious gastrointestinal (GI) events (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).</p>
<p><span class="Italics">Status Post Coronary Artery Bypass Graft (CABG) Surgery </span><br>Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. NSAIDs are contraindicated in the setting of CABG (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span>). </p>
<p><span class="Italics">Post-MI Patients</span><br>Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the first year <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">post MI</span> was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> declined somewhat after the first year post-MI, the increased relative risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in NSAID users persisted over at least the next four years of follow-up.</p>
<p>Avoid the use of etodolac in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If etodolac is used in patients with a recent MI, monitor patients for signs of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span><br>NSAIDs, including etodolac, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including etodolac, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span><br>The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, NSAID use increased the risk of MI, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Additionally, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients treated with NSAIDs. Use of [active moiety] may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see <span class="Bold"><a href="#s43">Drug Interactions</a></span>).</p>
<p>Avoid the use of etodolac in patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> unless the benefits are expected to outweigh the risk of worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. If etodolac is used in patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, monitor patients for signs of worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p><span class="Bold Italics">Gastrointestinal (GI) Effects - Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</span><br>NSAIDs, including etodolac, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for 1 year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk. Physicians should inform patients about the signs and/or symptoms of serious GI toxicity and what steps to take if they occur.</p>
<p>NSAIDs should be prescribed with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, and who use NSAIDs have a greater than 10-fold risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> than patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly of debilitated patients, and therefore, special care should be taken in treating this population. </p>
<p>To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
<p><span class="Italics">Renal Effects</span><br>Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at a greater risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
<p>Renal pelvic transitional epithelial <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, a spontaneous change occurring with variable frequency, was observed with increased frequency in treated male rats in a 2-year chronic study.</p>
<p><span class="Italics">Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></span><br>No information is available from controlled clinical studies regarding the use of etodolac in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with etodolac is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If etodolac therapy must be initiated, close monitoring of the patient’s renal function is advisable.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span><br>As with other NSAIDS, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without prior exposure to etodolac. Etodolac should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs. Fatal reactions have been reported in such patients (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s36">PRECAUTIONS</a></span>, <span class="Bold"><a href="#s37">General</a></span>, <span class="Bold"></span><span class="Bold Italics"><a href="#s40">Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>). Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span></p>
<p>NSAIDs, including etodolac, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Bold">Pregnancy</span></p>
<p>In late pregnancy, the third trimester, as with other NSAIDs, etodolac should be avoided because it may cause premature closure of the ductus arteriosus (see <span class="Bold"><a href="#s36">PRECAUTIONS</a></span>, <span class="Bold"><a href="#s36">Pregnancy</a></span>, <span class="Bold Italics"><a href="#s58">Non-teratogenic Effects</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s36"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS </h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s37"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">General </span></h2>
<p class="First">Etodolac cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered solely if a decision is made to discontinue corticosteroids. </p>
<p>The pharmacological activity of etodolac in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Bold">Hepatic Effects </span></h3>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including etodolac. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes, have been reported. </p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with etodolac. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), etodolac should be discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="Bold">Hematological Effects </span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs including etodolac. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including etodolac, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. </p>
<p>NSAIDS inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving etodolac who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-7.1.3"></a><p></p>
<h3><span class="Bold">Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> </span></h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmas</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, etodolac should not be administered to patients with this form of aspirin sensitivity and should be used with caution in all patients with pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s41"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Information For Patients </span></h2>
<p class="First"><span class="Bold">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</span></p>
<ol class="Arabic">
<li>
<span class="Bold">Cardiovascular Thrombotic Events</span><br>Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or slurring of speech, and to report any of these symptoms to their health care provider immediately (see<span class="Italics"></span><span class="Bold"><a href="#s25"> WARNINGS</a></span>).</li>
<li>Etodolac, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <span class="Bold"><a href="#s30">WARNINGS, Gastrointestinal Effects, Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a>)</span>. </li>
<li>Etodolac, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible. </li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> And <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span><br>Advise patients to be alert for the symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and to contact their healthcare provider if such symptoms occur (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). </li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and “flu-like? symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy. </li>
<li>Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). </li>
<li>In late pregnancy, the third trimester, as with other NSAIDs, etodolac should be avoided because it may cause premature closure of the ductus arteriosus. </li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s42"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Laboratory Tests </span></h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically for signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Appropriate measures should be taken in case such signs of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> occur. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) and if abnormal liver tests are detected, persist or worsen, etodolac should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s43"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">Drug Interactions </span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-7.4.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">ACE-inhibitors</span><br>Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors (see <span class="Bold"><a href="#s36">PRECAUTIONS</a></span>, <span class="Bold"><a href="#s37">General</a></span>, <span class="Bold Italics"><a href="#s37">Renal Effects</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-7.4.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Antacids</span><br>The concomitant administration of antacids has no apparent effect on the extent of absorption of etodolac. However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-7.4.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Aspirin</span><br>When etodolac is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of etodolac and aspirin is not generally recommended because of the potential of increased adverse effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-7.4.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Cyclosporine, Digoxin, Methotrexate</span><br>Etodolac, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity. <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> associated with cyclosporine may also be enhanced. Patients receiving these drugs who are given etodolac, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs. NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-7.4.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Diuretics</span><br>Etodolac has no apparent <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> when administered with furosemide or hydrochlorothiazide. Nevertheless, clinical studies, as well as postmarketing observations have shown that etodolac can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <span class="Bold"><a href="#s31">WARNINGS, </a></span><span class="Bold Italics"><a href="#s31">Renal Effects</a></span><span class="Bold"></span>), as well as to assure diuretic efficacy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-7.4.6"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Glyburide</span><br>Etodolac has no apparent <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> when administered with glyburide. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-7.4.7"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Lithium</span><br>NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-7.4.8"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Phenylbutazone</span><br>Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac. Although <span class="Italics">in vivo</span> studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-7.4.9"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Phenytoin</span><br>Etodolac has no apparent <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> when administered with phenytoin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-7.4.10"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold Italics">Warfarin</span><br>The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than that of users of either drug alone. Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and <span class="Sup"></span>etodolac results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin. There was no significant difference in the pharmacodynamic effect of warfarin administered alone and warfarin administered with etodolac as measured by <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. Thus, concomitant therapy with warfarin and etodolac should not require dosage adjustment of either drug. However, caution should be exercised because there have been a few spontaneous reports of prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times, with or without <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, in etodolac-treated patients receiving concomitant warfarin therapy. </p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s54"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions </h2>
<p class="First">The urine of patients who take etodolac can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of etodolac. Diagnostic dip-stick methodology, used to detect <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketone bodies</span> in urine, has resulted in false-positive findings in some patients treated with etodolac. Generally, this phenomenon has not been associated with other clinically significant events. No dose relationship has been observed. </p>
<p>Etodolac treatment is associated with a small decrease in serum uric acid levels. In clinical trials, mean decreases of 1 to 2 mg/dL were observed in arthritic patients receiving etodolac (600 mg to 1000 mg/day) after 4 weeks of therapy. These levels then remained stable for up to 1 year of therapy. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s55"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility </h2>
<p class="First">No carcinogenic effect of etodolac was observed in mice or rats receiving oral doses of 15 mg/kg/day (45 to 89 mg/m<span class="Sup">2</span>, respectively) or less for periods of 2 years or 18 months, respectively. Etodolac was not mutagenic in <span class="Italics">in vitro</span> tests
performed with <span class="Italics">S. typhimurium</span> and mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells as well as in an <span class="Italics">in vivo</span> mouse micronucleus test. However, data from the <span class="Italics">in
vitro</span> human peripheral lymphocyte test showed an increase in the number of gaps (3.0 to 5.3% unstained regions in the chromatid without <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">dislocation</span>) among the etodolac-treated cultures (50 to 200 mcg/mL) compared to negative controls (2.0%); no other difference was noted between the controls and drug-treated groups. Etodolac showed no impairment of fertility in male and female rats up to oral doses of 16 mg/kg (94 mg/m<span class="Sup">2</span>). However, reduced implantation of fertilized eggs occurred in the 8 mg/kg group. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s56"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s57"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold Italics">Teratogenic Effects - Pregnancy Category C </span></h3>
<p class="First">In teratology studies, isolated occurrences of alterations in limb development were found and included <span class="product-label-link" type="condition" conceptid="74740" conceptname="Polydactyly">polydactyly</span>, oligodactyly, <span class="product-label-link" type="condition" conceptid="4162283" conceptname="Syndactyly">syndactyly</span>, and unossified phalanges in rats and oligodactyly and synostosis of metatarsals in rabbits. These were observed at dose levels (2 to 14 mg/kg/day) close to human clinical doses. However, the frequency and the dosage group distribution of these findings in initial or repeated studies did not establish a clear drug or dose-response relationship. Animal reproduction studies are not always predictive of human response. There are no adequate or well-controlled studies in pregnant women. Etodolac should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s58"></a><a name="section-7.7.2"></a><p></p>
<h3><span class="Bold Italics">Nonteratogenic Effects </span></h3>
<p class="First">Etodolac should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. Because of the known effects of NSAIDs on parturition and on the human fetal cardiovascular system with respect to closure of the ductus arteriosus, use during late pregnancy should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s59"></a><a name="section-7.8"></a><p></p>
<h2>Labor and Delivery </h2>
<p class="First">In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of etodolac on labor and delivery in pregnant women are unknown. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s60"></a><a name="section-7.9"></a><p></p>
<h2>Nursing Mothers </h2>
<p class="First">It is not known whether etodolac is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from etodolac, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s61"></a><a name="section-7.10"></a><p></p>
<h2>Pediatric Use </h2>
<p class="First">Safety and effectiveness in pediatric patients below the
age of 18 years have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s62"></a><a name="section-7.11"></a><p></p>
<h2>Geriatric Use </h2>
<p class="First">As with any NSAID, caution should be exercised in treating the elderly (65 years and older) and when increasing the dose (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). </p>
<p>In etodolac clinical studies, no overall differences in safety or effectiveness were observed between these patients and younger patients. In pharmacokinetic studies, age was shown not to have any effect on etodolac half-life or protein binding, and there was no change in expected drug accumulation. Therefore, no dosage adjustment is generally necessary in the elderly on the basis of pharmacokinetics (see <span class="Bold"><a href="#s13">CLINICAL PHARMACOLOGY, Special Populations</a></span>). </p>
<p>Elderly patients may be more sensitive to the antiprostaglandin effects of NSAIDs (on the gastrointestinal tract and kidneys) than younger patients (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). In particular, elderly or debilitated patients who receive NSAID therapy seem to tolerate gastrointestinal ulceration or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well than other individuals, and most spontaneous reports of fatal GI events are in this population. </p>
<p>Etodolac is eliminated primarily by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <span class="Bold"><a href="#s36">PRECAUTIONS</a></span>, <span class="Bold"></span><span class="Bold Italics"><a href="#s36">Renal Effects</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s63"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<p class="First">In patients taking etodolac or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1-10% of patients are: </p>
<p><span class="Bold">Gastrointestinal experiences including</span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/perforation, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (gastric/duodenal), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p><span class="Bold">Other events including</span>: abnormal renal function, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. </p>
<p>Adverse-reaction information for etodolac was derived from 2,629 arthritic patients treated with etodolac in double-blind and open-label clinical trials of 4 to 320 weeks in duration and worldwide postmarketing surveillance studies. In clinical trials, most adverse reactions were mild and transient. The discontinuation rate in controlled clinical trials, because of adverse events, was up to 10% for patients treated with etodolac. </p>
<p>New patient complaints (with an incidence greater than or equal to 1%) are listed below by body system. The incidences were determined from clinical trials involving 465 patients with <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> treated with 300 to 500 mg of etodolac b.i.d. (i.e., 600 to 1000 mg/day). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-8.1"></a><p></p>
<h2>Incidence Greater Than Or Equal To 1% - Probably Causally Related </h2>
<p class="First">Body as a whole - <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. </p>
<p>Digestive system - <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> (10%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>*, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>*, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>*, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>*, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </p>
<p>Nervous system - <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>*, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>*, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>. </p>
<p>Skin and appendages - <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. </p>
<p>Special senses - <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. </p>
<p>Urogenital system - <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
<p></p>
<p></p>
<p>* Drug-related patient complaints occurring in 3 to 9% of patients treated with etodolac.<br>  Drug-related patient-complaints occurring in fewer than 3%, but more than 1%, are unmarked. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-8.2"></a><p></p>
<h2>Incidence Less Than 1% - Probably Causally Related </h2>
<p class="First">(Adverse reactions reported only in worldwide postmarketing experience, not seen in clinical trials, are considered rarer and are italicized.) </p>
<p>Body as a whole - <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>).</span></p>
<p>Cardiovascular system - <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> (including necrotizing and allergic).</span></p>
<p>Digestive system - <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, elevated liver enzymes, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>,</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>,</span> <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with or without <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and/or perforation<span class="Italics">,
<span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulceration</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</span></p>
<p>Hemic and lymphatic system - <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> increased, <span class="Italics"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</span></p>
<p>Metabolic and nutritional - <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>, serum creatinine increase, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> in previously controlled diabetic patients.</span></p>
<p>Nervous system - <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. </p>
<p>Respiratory system - <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="Italics">pulmonary infiltration with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>.</span></p>
<p>Skin and appendages - <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span> with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></span>, hyperpigmentation<span class="Italics">, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>.</span></p>
<p>Special senses - <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">Photophobia</span>, transient <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. </p>
<p>Urogenital system - <span class="Italics">Elevated BUN, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-8.3"></a><p></p>
<h2>Incidence Less Than 1% - Causal Relationship Unknown </h2>
<p class="First">(Medical events occurring under circumstances where causal relationship to etodolac is uncertain. These reactions are listed as alerting information for physicians.) </p>
<p>Body as a whole - <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. </p>
<p>Cardiovascular system - <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>. </p>
<p>Digestive system - <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span> with or without stricture or <span class="product-label-link" type="condition" conceptid="318186" conceptname="Achalasia of esophagus">cardiospasm</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. </p>
<p>Metabolic and nutritional - Change in weight. </p>
<p>Nervous system - <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. </p>
<p>Respiratory system - <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>. </p>
<p>Skin and appendages - <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin peeling</span>. </p>
<p>Special senses - <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>. </p>
<p>Urogenital system - <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> irregularities. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-8.4"></a><p></p>
<h2>Additional Adverse Reactions Reported with NSAIDS </h2>
<p class="First">Body as a whole - <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </p>
<p>Cardiovascular system - <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> </p>
<p>Digestive system - <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric ulcers</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span> </p>
<p>Hemic and lymphatic system - <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span> </p>
<p>Nervous system - <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> </p>
<p>Respiratory system - <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </p>
<p>Urogenital system - <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>/<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s68"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE </h1>
<p class="First">Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are usually limited
to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are
generally reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur
and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> has occurred following massive ibuprofen or mefenamic-acid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur but
are rare. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion
of NSAIDs, and may occur following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
<p>Patients
should be managed by symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
There are no specific antidotes. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and/or activated charcoal (60 to 100 g
in adults, 1 to 2 g/kg in children) and/or osmotic cathartic
may be indicated in patients seen within 4 hours of ingestion with symptoms
or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>,
alkalinization of the urine, hemodialysis, or hemoperfusion would probably
not be useful due to etodolac's high protein binding. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s69"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First">Carefully consider the potential benefits and risks of etodolac and other treatment options before deciding to use etodolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). </p>
<p>After observing the response to the initial therapy with etodolac, the dose and frequency should be adjusted to suit an individual patient's needs. </p>
<p>Dosage adjustment of etodolac is generally not required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Etodolac should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold"><a href="#s31">WARNINGS, </a></span><span class="Bold Italics"><a href="#s31">Renal Effects</a></span><span class="Bold"></span>). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> </h2>
<p class="First">The recommended total daily dose of etodolac for <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> is up to 1000 mg, given as 200-400 mg every 6 to 8 hours. Doses of etodolac greater than 1000 mg/day have not been adequately evaluated in well-controlled clinical trials. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> </h2>
<p class="First">The recommended starting dose of etodolac for the management of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> or <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> is: 300 mg b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. A lower dose of 600 mg/day may suffice for long-term administration. Physicians should be aware that doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials. </p>
<p>In chronic conditions, a therapeutic response to therapy with etodolac is sometimes seen within one week of therapy, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s72"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED </h1>
<p class="First">Etodolac Tablets, USP are available as:</p>
<p>400 mg Tablets (White to off-white, oval, unscored, film-coated tablets, imprinted "APO 041" on one side and "400" on the other side.)</p>
<p>- in bottles of 100, NDC 60505-0041-1 <br>- in bottles of 500, NDC 60505-0041-2<br></p>
<p>500 mg tablets (White to off-white, oval, unscored, film-coated tablets imprinted "APO 102" on one side and "500" on the other side.)</p>
<p>- in bottles of 100, NDC 60505-0102-1 <br>- in bottles of 500, NDC 60505-0102-2</p>
<p>Store at 20° to 25°C (68° to 77°F); excursions permitted from 15°C to 30° (59° to 86°F) [see USP Controlled Room Temperature].  </p>
<p>Dispense in a tight, light-resistant container [see USP].</p>
<p><span class="Bold">APOTEX INC. <br>ETODOLAC TABLETS, USP <br>400 mg and 500 mg</span></p>
<table width="45%">
<col width="25%">
<col width="20%">
<tbody class="Headless"><tr class="First Last">
<td>
<span class="Bold">Manufactured by</span><p class="First"> Apotex Inc.</p>
<p>Toronto, Ontario</p>
<p>Canada M9L 1T9</p>
</td>
<td>
<span class="Bold">Manufactured for</span><p class="First">Apotex Corp.</p>
<p>Weston, Florida</p>
<p>33326</p>
</td>
</tr></tbody>
</table>
<p>Revised: July 2015</p>
<p>Rev. 3</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="_1ba849be-f3dc-21a6-92f2-9f11880344d4"></a><a name="section-12"></a><p></p>
<h1><span class="Bold Underline">Medication Guide</span></h1>
<p class="First"><span class="Bold"><span class="Underline">for </span></span></p>
<p><span class="Bold"><span class="Underline">Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</span></span></p>
<p><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<p><span class="Bold">What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAIDs can cause serious side effects, including:</span><span class="Bold"></span></p>
<ul><li>
<span class="Bold"><span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </span><span class="Bold"> </span></span><span class="None">Increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span><ul>
<li>with increasing doses of NSAIDs</li>
<li>with longer use of NSAIDs</li>
</ul>
<p class="First"><span class="Sub"></span></p>
</li></ul>
<p><span class="Bold"></span><span class="Bold">Do not take NSAIDs right before or after heart surgery called a “coronary artery bypass graft (CABG)?. Avoid taking NSAIDs after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, unless your healthcare provider tells you to. You may have an increased risk of another <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> if you take NSAIDs after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span><span class="Bold"></span></p>
<p></p>
<ul><li>
<span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intest</span><span class="Bold">ines: </span><ul>
<li> at anytime <span class="Bold">during use</span>
</li>
<li>without warning symptoms</li>
<li>that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
</li></ul>
<p><span class="Bold"><span class="Bold">The risk of getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with</span>:</span></p>
<ul>
<li>past history of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span>, or stomach or intestinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with use of NSAIDs</li>
<li>taking medicines called “corticosteroids?, “anticoagulants?, “SSRIs?, or “SNRIs?</li>
<li>increasing doses of NSAIDs</li>
<li>longer use of NSAIDs</li>
<li>smoking</li>
<li>drinking alcohol</li>
<li>older age</li>
<li>poor health</li>
<li>advanced liver disease</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</li>
</ul>
<p><span class="Bold">NSAIDs medicines should only be used:</span></p>
<ul>
<li>exactly as prescribed</li>
<li>at the lowest dose possible for your treatment</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What are NSAIDs?</span></p>
<p>NSAIDs are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span>, and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Bold">Who should not take a NSAIDs?</span></p>
<p><span class="Bold">Do not take an NSAIDs:</span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAIDs</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery </li>
</ul>
<p><span class="Bold"></span><span class="Bold">Before taking NSAIDS, tell </span><span class="Bold">your healthcare provider</span> <span class="Bold">about all of your medical conditions, including if you:</span></p>
<ul>
<li>have liver or kidney problems</li>
<li>have high blood pressure <span class="None"></span>
</li>
<li>have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li>are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy.<span class="Bold"> </span><span class="Bold">You should not take NSAIDs after 29 weeks of pregnancy.</span>
</li>
<li>are breastfeeding or plan to breast feed.</li>
</ul>
<p><span class="Bold"></span><span class="Bold">Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements. </span>NSAIDs and some other medicines can interact with each other and cause serious side effects.<span class="Bold"> </span><span class="Bold">Do not start taking any new medicine without talking to your healthcare provider first.</span><span class="Bold"></span></p>
<p><span class="Bold">What are the possible side effects of NSAIDs?</span></p>
<p><span class="Bold">NSAIDs can cause serious side effects including:</span></p>
<p><span class="Bold">See “What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)? </span></p>
<ul>
<li>new or worse high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> </li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>
<span class="Bold">Other side effects of NSAIDs include:</span> <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, gas, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
<p><span class="Bold">Get emergency help right away if you get any of the following symptoms:</span></p>
<table><tbody class="Headless"><tr class="First Last">
<td><ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
</ul></td>
<td><ul>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul></td>
</tr></tbody></table>
<p><span class="Bold">Stop taking NSAID and call your healthcare provider right away if you get any of the following symptoms:</span></p>
<table><tbody class="Headless"><tr class="First Last">
<td><ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span> or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
</ul></td>
<td><ul>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms, legs, hands and feet</li>
</ul></td>
</tr></tbody></table>
<p><span class="Bold">If you take too much of your NSAID, call your healthcare provider or get medical help right away.</span><span class="Bold"></span></p>
<p>These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">Other information about NSAIDs:</span></p>
<ul>
<li>Aspirin is an NSAID but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines. </li>
<li>Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><span class="Bold">General information about the safe and effective use of NSAIDs </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them. </p>
<p>If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.</p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<table width="45%">
<col width="25%">
<col width="20%">
<tbody class="Headless"><tr class="First Last">
<td>
<span class="Bold">Manufactured by</span><p class="First"> Apotex Inc.</p>
<p>Toronto, Ontario</p>
<p>Canada M9L 1T9</p>
</td>
<td>
<span class="Bold">Manufactured for</span><p class="First">Apotex Corp.</p>
<p>Weston, Florida</p>
<p>33326</p>
</td>
</tr></tbody>
</table>
<p>Revised: July 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_326a9d5e-2870-1d25-e65b-19d48691835f"></a><a name="section-13"></a><p></p>
<h1>
<span class="Bold">PRINCIPAL DISPLAY PANEL</span> - <span class="Bold">400 MG</span>
</h1>
<p class="First">Representative sample of labeling (see the<span class="Bold"><a href="#s72"> HOW SUPPLIED </a></span>section for complete listing):</p>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 400 mg BOTTLE LABEL</span></p>
<p><span class="Bold">APOTEX CORP. </span>NDC 60505-0041-1</p>
<p><span class="Bold">ETODOLAC TABELTS USP</span></p>
<p>400 mg</p>
<p><span class="Bold">Rx only</span></p>
<p>100 Tablets</p>
<p><img alt="400mg-100btl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4d682f98-1e8a-4c2b-6df3-169d2ed10dc1&amp;name=400mg-100btl.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_32962b98-c4e5-cffb-9d44-edf84e6274a4"></a><a name="section-14"></a><p></p>
<h1> PRINCIPAL DISPLAY PANEL- 500MG</h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 500 mg </span></p>
<p><span class="Bold">BOTTLE LABEL</span> <span class="Bold">APOTEX CORP. </span></p>
<p>NDC 60505-0102-1<span class="Bold"></span></p>
<p><span class="Bold">ETODOLAC TABELTS USP</span> </p>
<p>500 mg<span class="Bold"></span></p>
<p><span class="Bold">Rx only</span> </p>
<p>100 Tablets</p>
<p><img alt="500mg-100btl" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4d682f98-1e8a-4c2b-6df3-169d2ed10dc1&amp;name=500mg-100btl.jpg">  </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ETODOLAC 		
					</strong><br><span class="contentTableReg">etodolac tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0041</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETODOLAC</strong> (ETODOLAC) </td>
<td class="formItem">ETODOLAC</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (100 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (100 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 1500</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;041;400</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-0041-1</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-0041-2</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076004</td>
<td class="formItem">05/01/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ETODOLAC 		
					</strong><br><span class="contentTableReg">etodolac tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60505-0102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETODOLAC</strong> (ETODOLAC) </td>
<td class="formItem">ETODOLAC</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (100 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLCELLULOSE (100 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 1500</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">APO;102;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60505-0102-1</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:60505-0102-2</td>
<td class="formItem">500  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076004</td>
<td class="formItem">05/01/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Apotex Corp.
							(845263701)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Apotex Inc. (209429182)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Apotex Inc.</td>
<td class="formItem"></td>
<td class="formItem">205576023</td>
<td class="formItem">manufacture(60505-0041, 60505-0102), analysis(60505-0041, 60505-0102)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8d805e6b-fe15-913b-8c95-05c328ce8a82</div>
<div>Set id: 4d682f98-1e8a-4c2b-6df3-169d2ed10dc1</div>
<div>Version: 5</div>
<div>Effective Time: 20150723</div>
</div>
</div> <div class="DistributorName">Apotex Corp.</div></p>
</body></html>
